Fate Therapeutics vs HCW Biologics
Fate Therapeutics is the larger business, with $6.6m of revenue in fiscal 2025 against $54,232 for HCW Biologics (122.5 times as much). Fate Therapeutics grew faster (-51.2% against -97.9%). Fate Therapeutics kept more of each dollar of sales as profit: a net margin of -2051.1% against -14677.1%. Fate Therapeutics carries less debt relative to equity (0.0% against 246.3%).
| Latest fiscal year | Fate TherapeuticsFATE, 2025 | HCW BiologicsHCWB, 2025 |
|---|---|---|
| Revenue | $6.6m | $54,232 |
| Revenue growth | -51.2% | -97.9% |
| Net income | −$136m | −$8.0m |
| Operating margin | -2222.4% | -24270.7% |
| Net margin | -2051.1% | -14677.1% |
| Return on equity | -51.8% | — |
| Free cash flow | −$112m | −$13.4m |
| Cash | $46.6m | $2.0m |
| Total debt | $0 | $6.8m |
| Debt to equity | 0.0% | 246.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 161 | 35 |
| Market value | $236m | $1.5m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 6 sales | 6 buys, 0 sales |